Company
Headquarters: Toyama, Japan
Employees: 2,725
CEO: Mr. Yuiichi Tamura
¥2.47 Billion
JPY as of March 1, 2023
US$17.1 Million
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Nichi-Iko Pharmaceutical Co., Ltd. manufactures, sells, imports, and distributes various pharmaceutical products. The company operates through two segments, Sagent Group and Nichi-Iko Group. It primarily focuses on the production of generic drugs. The company offers antidiabetic agents, antacids, antireflux agents, beta-blocker, hypnotic and sedative, angiotensin ? antagonist, angiotensin ? antagonist/diuretic combination, dyslipidaemic agent, and calcium antagonist products. It also provides treatments for circulatory, digestive, respiratory, central and peripheral nervous systems, and others. In addition, the company engages in the packaging design business. Further, it exports its products. The company was formerly known as Nihon Iyakuhin Kogyo Co., Ltd. and changed its name to Nichi-Iko Pharmaceutical Co., Ltd. in 2005. Nichi-Iko Pharmaceutical Co., Ltd. was incorporated in 1947 and is headquartered in Toyama, Japan.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Nichi-Iko Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: JPX: 4541 wb_incandescent